Rapid Test Ag 2019-nCov is a lateral-flow test with high sensitivity for detecting SARS-CoV-2 antigen (nucleocapsid protein) in patient-friendly nasal (or nasopharyngeal) swab specimens.

The nasal sampling method is less invasive and provides a more comfortable testing experience without compromising result accuracy. Nasal procedure is ideal for sensitive individual groups such as children, elderly persons, and people with disabilities.

Clinical Performance Characteristics

The Rapid Test Ag 2019-nCov demonstrated a sensitivity of 96.33% and specificity of 99.62% in an independent clinical trial performed at the Laboratory of Microbiology of the General University Hospital of Larissa, Greece. This is one of the major Reference Laboratories for SARS-CoV-2 testing in Greece during the pandemic.

Moreover, the ProGnosis Biotech test is listed in the IVD Devices and Test Methods Database of the European Commission, the German Federal Institute for Drugs and Medical Devices (in accordance with the standards set by Robert-Koch- and Paul Ehrlich Institutes) and is also registered in the Italian Ministry of Health. 

Please note: Test should only be conducted by medical personnel.

Click here to ​learn more about the Rapid Test Ag 2019-nCov. 

Watch Testing Procedure: